Close Menu

Alcon

Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Solid Cancers
Patent Number: 8,148,069
Filed: Jan. 3, 2007

Silence Therapeutics has scored a victory in its efforts to defend its intellectual property estate, announcing this week that the US Patent and Trademark Office has upheld the validity of four patents related to the design of RNAi molecules.

Title: Oncogenic ALL-1 Fusion Proteins for Targeting Drosha-Mediated microRNA Processing
Patent Number: 8,053,186
Filed: June 13, 2008
Inventor: Carlo Croce, Ohio State University

The patent, EP1633890, is part of the so-called Zamore IP estate and claims rules for designing RNAi molecules with improved potency and fewer off-target effects.

Pages

Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.

Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.

Slate's Jane Hu compares some at-home genetic tests to astrology.

In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.